trending Market Intelligence /marketintelligence/en/news-insights/trending/-E_lmq-a9E2O3G4ON3jAzw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Motus GI launches common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Motus GI launches common stock offering

Motus GI Holdings Inc. launched a public offering of 5 million common shares.

Piper Jaffray & Co. is acting as the sole underwriter for the offer. The Fort Lauderdale, Fla.-based medical technology company plans to grant the underwriter a 30-day option to buy an additional 750,000 common shares.

Motus GI plans to use proceeds to fund commercialization and research and development activities, including the clinical and regulatory development of its product Pure-Vu. The Pure-Vu System is cleared by the U.S. Food and Drug Administration to help clean a poorly prepared colon during colonoscopy.

Part of the proceeds will also be used for working capital and general corporate purposes.